Clinical trials: Monoclonal
Multiple Sclerosis, Relapsing-Remitting
Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis
The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis.
- Trial name
- ANGEL-MS (NCT03239860)
- Testing
- GNbAC1 Monoclonal Antibody
- Where
- 12 sites in Bulgaria, Croatia and 10 more
- Volunteers
- 220 people
- Sponsor
- GeNeuro SA
Selected Advanced Solid Tumors
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
TRM-010 is a first-in-human (FIH) clinical study designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of EOS006215, a fully human monoclonal antibody that…
- Trial name
- NCT06877533
- Testing
- EOS006215, Anticancer agent
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- iTeos Belgium SA
Biliary Tract Neoplasms, Cholangiocarcinoma
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Background: Biliary tract cancers are rare but they are serious. Researchers want to see if a certain drug helps the immune system fight cancer cells. The drug is called pembrolizumab.
- Conditions
- Biliary Tract Neoplasms, Cholangiocarcinoma, Bile Duct Cancer, Liver Cancer
- Trial name
- NCT03111732
- Testing
- Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
This randomized phase III trial studies 90-yttrium ibritumomab tiuxetan and combination chemotherapy compared with combination chemotherapy alone before stem cell transplant in treating patients with diffuse large b-cell…
- Trial name
- SPINOZA (NCT02366663)
- Testing
- 90-Yttrium Ibritumomab tiuxetan, Carmustine, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Colorectal Neoplasms, Colorectal Carcinoma
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
To estimate progression-free survival at one year in elderly patients with RAS/BRAF wild-type unresectable mCRC and good performance status treated with FOLFIRI + panitumumab as first-line therapy.
- Conditions
- Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Cancer Metastatic, Neoplasm Metastasis
- Trial name
- OPALO (NCT03142516)
- Testing
- Panitumumab, Irinotecan, Folinic acid
- Where
- 12 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Short-course Radiotherapy Plus Chemotherapy, Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab
Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer
Safety and efficacy of Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab versus Short-course Radiotherapy plus Chemotherapy as Total Neoadjuvant…
- Trial name
- SPARK II (NCT07674732)
- Testing
- Short-course Radiotherapy plus Chemotherapy, Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Dechang Diao
Solid Advanced Tumor, Lymphoma
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
This is a phase 1/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.
- Conditions
- Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- NCT05751798
- Testing
- Part A: OSE-279 100mg, Part A: OSE-279 300mg, Part A: OSE-279 600mg
- Where
- 11 sites in Belgium, France and 1 more
- Volunteers
- 41 people
- Sponsor
- OSE Immunotherapeutics
HIV-1-infection
10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults
This is an open-label phase 1b clinical trial enrolling people living with HIV (PLWH) who are antiretroviral therapy (ART)-naïve or have not been on ART for > 24 weeks.
- Trial name
- NCT05890963
- Testing
- ART, 10E8.4/iMab, VRC07-523LS
- Where
- Tanzania
- Volunteers
- 20 people
- Sponsor
- David Ho
Allergic Rhinitis
Study of CM310 in Patients With Allergic Rhinitis
This study is a multicenter, single arm, open-label phase II clinical study mainly evaluating the safety of CM310 in patients with allergic rhinitis.
- Trial name
- NCT05908721
- Testing
- CM310
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Keymed Biosciences Co.Ltd
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g.…
- Conditions
- Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
- Trial name
- NCT05312255
- Testing
- Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Roswell Park Cancer Institute
Respiratory Syncytial Virus Infections
Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524
MEDI-524 given for up to 5 doses at 3 and 15 mg/kg to high-risk children appeared to be safe and well tolerated.
- Trial name
- NCT00192478
- Testing
- Medi-524
- Where
- 3 sites in Argentina, Chile
- Volunteers
- 217 people
- Sponsor
- MedImmune LLC
Breast Cancer
Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2
Randomized phase II trial to study the effectiveness of chemotherapy with paclitaxel and the monoclonal antibody trastuzumab followed by chemotherapy in treating women who have stage II or stage IIIA breast cancer that…
- Trial name
- NCT00003992
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 45 sites in United States, South Africa
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Primary Sclerosing Cholangitis
A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis
This is a phase II study to determine the safety and preliminary efficacy of a human monoclonal antibody (BTT1023) which targets the vascular adhesion protein (VAP-1) and its use in the treatment of patients with primary…
- Trial name
- BUTEO (NCT02239211)
- Testing
- BTT1023
- Where
- 6 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- University of Birmingham
Lymphoma
Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00072449
- Testing
- rituximab
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma
The purpose of this study is to look at the efficacy and safety of sintilimab in combination with carboplatin and nab-paclitaxel in patients with oral cavity or oropharyngeal squamous cell carcinoma who are about to undergo…
- Trial name
- OOC-001 (NCT04718415)
- Testing
- sintilimab, paclitaxel, carboplatin, Surgical resection
- Where
- 2 sites in China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have recurrent or persistent metastatic colorectal cancer.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00023933
- Testing
- iodine I 131 monoclonal antibody CC49-deltaCH2
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer, Colorectal Cancer Metastatic
Sym004 Versus TAS-102 in Patients With mCRC
This is a Phase 3, randomized, open-label, 2-arm trial designed to evaluate overall survival (OS) following treatment with Sym004, an investigational medicinal product (IMP), versus TAS-102 (trifluridine/tipiracil), a comparator…
- Conditions
- Metastatic Colorectal Cancer, Colorectal Cancer Metastatic, Carcinoma
- Trial name
- NCT03717038
- Testing
- Sym004, TAS-102
- Sponsor
- Symphogen A/S
Advanced or Metastatic Solid Tumor Malignancies
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally…
- Trial name
- NCT06258304
- Testing
- GIGA-564
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- GigaGen, Inc.
Advanced Unresectable Solid Tumors
Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
M108 is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. The aim of this phase I study is to establish safety and Tolerability of different Dosage regimen in patients With Advanced Unresectable…
- Trial name
- NCT04894825
- Testing
- M108
- Where
- China
- Volunteers
- 152 people
- Sponsor
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic
Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects
This is a randomized, double-blind, single-dose, parallel-group study comparing pharmacokinetic characteristics, safety , tolerability and immunogenicity of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth…
- Conditions
- Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent
- Trial name
- NCT05110118
- Testing
- LY01008, Avastin
- Where
- China
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Shandong Boan Biotechnology Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.